Similar articles

• Alemtuzumab and multiple sclerosis: therapeutic application.

  Minagar A, Alexander JS, Sahraian MA, Zivadinov R. Minagar A, et al. Expert Opin Biol Ther. 2010 Mar;10(3):421-9. doi: 10.1517/14712591003586806. Expert Opin Biol Ther. 2010. PMID: 20095876 Review.
• Melanoma following treatment with alemtuzumab for multiple sclerosis.

  Pace AA, Zajicek JP. Pace AA, et al. Eur J Neurol. 2009 Apr;16(4):e70-1. doi: 10.1111/j.1468-1331.2009.02552.x. Eur J Neurol. 2009. PMID: 19222552 No abstract available.
• [Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis].

  Warnke C, Kieseier BC, Zettl U, Hartung HP. Warnke C, et al. Nervenarzt. 2009 Apr;80(4):468-74. doi: 10.1007/s00115-009-2681-9. Nervenarzt. 2009. PMID: 19296065 Review. German.
• Treating multiple sclerosis with monoclonal antibodies.

  Buttmann M, Rieckmann P. Buttmann M, et al. Expert Rev Neurother. 2008 Mar;8(3):433-55. doi: 10.1586/14737175.8.3.433. Expert Rev Neurother. 2008. PMID: 18345973 Review.
• [Alemtuzumab and multiple sclerosis].

  Nau JY. Nau JY. Rev Med Suisse. 2008 Nov 5;4(178):2425. Rev Med Suisse. 2008. PMID: 19051633 French. No abstract available.